Showing results 1 to 20 of 75
  Prevention of falls, bone loss and fractures : D-hormone analogs or native vitamin D? a meta-perspective; ; Reginster, Jean-Yves  in Osteoporosis International (2009, March), 20(Suppl.1), 90 Detailed reference viewed: 9 (1 ULg)Development and Validation of a Markov Microsimulation Model for the Economic Evaluation of Treatments in Osteoporosis.Hiligsmann, Mickaël ; Ethgen, Olivier ; Bruyère, Olivier et alin Value in Health (2009), 12(5), 687-696 ABSTRACT Objective: Markov models are increasingly used in economic evaluations of treatments for osteoporosis. Most of the existing evaluations are cohort-based Markov models missing comprehensive memory ... [more ▼] ABSTRACT Objective: Markov models are increasingly used in economic evaluations of treatments for osteoporosis. Most of the existing evaluations are cohort-based Markov models missing comprehensive memory management and versatility. In this article, we describe and validate an original Markov microsimulation model to accurately assess the cost-effectiveness of prevention and treatment of osteoporosis. Methods: We developed a Markov microsimulation model with a lifetime horizon and a direct health-care cost perspective. The patient history was recorded and was used in calculations of transition probabilities, utilities, and costs. To test the internal consistency of the model, we carried out an example calculation for alendronate therapy. Then, external consistency was investigated by comparing absolute lifetime risk of fracture estimates with epidemiologic data. Results: For women at age 70 years, with a twofold increase in the fracture risk of the average population, the costs per quality-adjusted life-year gained for alendronate therapy versus no treatment were estimated at Euro 9105 and Euro 15,325, respectively, under full and realistic adherence assumptions. All the sensitivity analyses in terms of model parameters and modeling assumptions were coherent with expected conclusions and absolute lifetime risk of fracture estimates were within the range of previous estimates, which confirmed both internal and external consistency of the model. Conclusion: Microsimulation models present some major advantages over cohort-based models, increasing the reliability of the results and being largely compatible with the existing state of the art, evidence-based literature. The developed model appears to be a valid model for use in economic evaluations in osteoporosis. [less ▲] Detailed reference viewed: 216 (30 ULg)Utility values associated with osteoporotic fracture: a systematic review of the literature.Hiligsmann, Mickaël ; Ethgen, Olivier ; et alin Calcified Tissue International (2008), 82(4), 288-92 We reviewed studies that have estimated the impact of osteoporotic fracture on quality-adjusted life years (QALY) and to determine reference values for countries that would like to carry out cost-utility ... [more ▼] We reviewed studies that have estimated the impact of osteoporotic fracture on quality-adjusted life years (QALY) and to determine reference values for countries that would like to carry out cost-utility analyses but that do not have their own values. The computerized medical literature databases Medline and EMBASE were searched from January 1990 to December 2006. The search was carried out in two steps. The first step was to identify studies that related to quality of life in osteoporosis. As part of the second step, only the studies that translated quality of life into a utility value (one single value for health status ranging 0-1) and calculated a utility loss over a period of at least 1 year were selected. From the 152 studies identified in the first analysis, only 16 were retained after the second step. Ten studies investigated utility values for hip fractures, 11 for vertebral fractures, five for distal forearm fractures, and four for other osteoporotic fractures and fracture interactions. Utility values differed substantially between studies, partly due to the valuation technique used, the severity of fractures, and the sample size. This review suggests that there is no meaningful average value across different studies, different samples, different countries, or different instruments. Although we tried to determine the best available values, these values do not preclude the need for country-specific studies. Finally, we also make recommendations regarding the design and methodology for such studies. [less ▲] Detailed reference viewed: 34 (8 ULg)NSAIDs in the management of musculoskeletal conditions: a comparative meta-analysis of the efficacy/safety profile of piroxicam; ; et al in Arthritis and Rheumatism (2007, September), 56(number 9 (suppl.)), 599-600 Detailed reference viewed: 6 (0 ULg)Rationale and development of an individual patient-based model to accurately assess the efficacy of osteoporosis managementHiligsmann, Mickaël ; ; Ethgen, Olivier et alin Osteoporosis International (2007, March), 18(S1), 169 Detailed reference viewed: 10 (3 ULg)Tendance dans l'utilisation de biphosphonates, de vitamine D et de calcium dans l'ostéoporose postménopausique : une analyse à 10 ans; Bruyère, Olivier ; Reginster, Jean-Yves in Revue du Rhumatisme (2006, December), 73 Detailed reference viewed: 4 (0 ULg)Self-reported versus measured prevalence of osteoporosis. An age-stratified analysis of its diagnostic coverage; Bruyère, Olivier ; et alin Osteoporosis International (2006, June), 17(Suppl.2), 45-46 Detailed reference viewed: 5 (3 ULg)Prescription and coprescription patterns of bone-active substances among postmenopausal women; Bruyère, Olivier ; Mawet, Audrey et alin Osteoporosis International (2006, June), 17(Suppl.2), 60 Detailed reference viewed: 5 (3 ULg)Longitudinal study of magnetic resonance imaging and fixed-flexion radiography to assess progression of osteoarthritis of the kneeBruyère, Olivier ; ; et alin Osteoporosis International (2006, March), 17(Suppl.1), 85 Detailed reference viewed: 3 (1 ULg)Self-reported versus measured prevalence of osteoporosis. An age-stratified analysis of its diagnostic coverage; Bruyère, Olivier ; et alin Osteoporosis International (2006, March), 17(Suppl.1), 93-94 Detailed reference viewed: 7 (1 ULg)Prescription and coprescription patterns of bone-active substances among postmenopausal women; Bruyère, Olivier ; Mawet, Audrey et alin Osteoporosis International (2006, March), 17(Suppl.1), 93 Detailed reference viewed: 5 (2 ULg)Self-reported versus measured prevalence of osteoporosis. An age-stratified analysis of its diagnostic coverage; Bruyère, Olivier ; et alin Arthritis and Rheumatism (2005, September), 52(number 9 (suppl.)), 228-229 Detailed reference viewed: 3 (1 ULg) Global prevalence and skeletal implications of vitamin D inadequacyReginster, Jean-Yves ; ; Rabenda, Véronique et alin Annals of the Rheumatic Diseases (2005, June), 64(Suppl.III), 362 Detailed reference viewed: 11 (4 ULg)Determinants of gastroprotective drugs co-prescription during treatment with non selective NSAIDS: A prospective survey of 2197 patients recruited in primary careRabenda, Véronique ; ; BELAICHE, Jacques et alin Osteoporosis International (2005, March), 16(Suppl.3), 101 Detailed reference viewed: 4 (1 ULg)Body composition, bone mineral density and Baecke physical activity scores in women aged 25 to 49 years; ; et al in Osteoporosis International (2005, March), 16(Suppl.3), 106 Detailed reference viewed: 4 (0 ULg)D-hormone analog alfacalcidol: its role in postmenopausal osteoporosis and rheumatoid arthritis management; DEROISY, Rita ; LECART, Marie-Paule et alin Osteoporosis International (2005, March), 16(Suppl.3), 105-106 Detailed reference viewed: 8 (1 ULg)Vitamin D inadequacy: global prevalence and skeletal implicationsReginster, Jean-Yves ; ; Rabenda, Véronique et alin Osteoporosis International (2005, March), 16(Suppl.3), 64 Detailed reference viewed: 10 (4 ULg)Health-related quality of life as a predictor of direct costs in osteoarthritisEthgen, Olivier ; ; et alin Osteoporosis International (2005, March), 16(Suppl.3), 59 Detailed reference viewed: 6 (1 ULg)Screening for osteoporosis: systematic DXA or pre-screening with questionnaires? An economic point of view; Ethgen, Olivier ; Bruyère, Olivier et alin Osteoporosis International (2005, March), 16(Suppl.3), 101 Detailed reference viewed: 3 (1 ULg)Responders to glucosamine sulfate in knee osteoarthritisBruyère, Olivier ; ; et alin Osteoporosis International (2005, March), 16(Suppl.3), 77 Detailed reference viewed: 7 (3 ULg) |
||
